Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

Yan Qiu; Chao-Ling Wan; Ming-Zhu Xu; Hai-Xia Zhou; Mei-Jing Liu; Wen-Jie Gong; Li-Qing Kang; Ai-Ning Sun; Lei Yu; De-Pei Wu; Chong-Sheng Qian; Sheng-Li Xue

doi:10.1038/s41408-023-00837-3

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

Blood Cancer J. 2023 May 3;13(1):66. doi: 10.1038/s41408-023-00837-3.

Authors

Yan Qiu^#^{1

2}, Chao-Ling Wan^#^{1

2}, Ming-Zhu Xu^#^{1

2}, Hai-Xia Zhou^#^{1

2}, Mei-Jing Liu^{1

2}, Wen-Jie Gong^{1

2}, Li-Qing Kang³, Ai-Ning Sun^{1

2}, Lei Yu^{3

4}, De-Pei Wu^{5

6}, Chong-Sheng Qian^{7

8}, Sheng-Li Xue^{9

10}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China.
³ Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, People's Republic of China.
⁴ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China.
⁵ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. drwudepei@163.com.
⁶ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. drwudepei@163.com.
⁷ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. qianchongsheng2006@163.com.
⁸ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. qianchongsheng2006@163.com.
⁹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. slxue@suda.edu.cn.
¹⁰ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. slxue@suda.edu.cn.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antigens, CD19
Burkitt Lymphoma*
Consolidation Chemotherapy
Hematopoietic Stem Cell Transplantation*
Humans
Immunotherapy, Adoptive / adverse effects
Receptors, Chimeric Antigen* / genetics
Sialic Acid Binding Ig-like Lectin 2

Substances

Receptors, Chimeric Antigen
Antigens, CD19
CD22 protein, human
Sialic Acid Binding Ig-like Lectin 2